ReNeuron Group plc
RENE.L · LSE
9/30/2023 | 3/31/2023 | 9/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | £0 | £0 | £0 | £0 |
| - Cash | £5 | £7 | £9 | £10 |
| + Debt | £0 | £0 | £0 | £1 |
| Enterprise Value | -£5 | -£7 | -£9 | -£9 |
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | 70.7% | -79% | 27% | – |
| Gross Profit | -£2 | -£1 | £0 | £0 |
| % Margin | -1,286.6% | -1,505.4% | 69.9% | 57.1% |
| EBITDA | -£3 | -£3 | -£2 | -£2 |
| % Margin | -2,051% | -2,993.5% | -457.8% | -704.6% |
| Net Income | -£3 | -£2 | -£3 | -£4 |
| % Margin | -1,809.6% | -2,426.1% | -725.1% | -1,291.3% |
| EPS Diluted | -0.05 | -0.039 | -0.056 | -0.078 |
| % Growth | -27.4% | 29.9% | 28.8% | – |
| Operating Cash Flow | -£2 | -£3 | -£4 | -£3 |
| Capital Expenditures | £0 | -£0 | -£0 | -£0 |
| Free Cash Flow | -£2 | -£3 | -£4 | -£3 |